An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

NCT02939274 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Verteporfin
DEVICE: Continuous Low-Irradiance Photodynamic Therapy (CLIPT)

Sponsor

Rogers Sciences Inc.